Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.
Leyden Labs is focused on developing intranasal products that aim to protect individuals from respiratory viruses, including those in the influenza and coronavirus families. The company's innovative approach targets common characteristics across various viral families, allowing for simultaneous protection against multiple viruses rather than just specific variants, as is the case with traditional vaccines. This strategy seeks to empower individuals to safeguard themselves from infections and reduce the transmission of these diseases. Leyden Labs is driven by a team of experienced biotechnology professionals who are committed to advancing solutions that alleviate the impact of respiratory viruses on public health.
Neurogene is a developer of generic medicines intended to improve patient outcomes for neurological disorders.The company's offerings include advancing genetic medicines for many neurological disorders where no effective treatment options exist, providing patients and families affected by rare neurological disorders with gene therapy that improves quality of life.
IDRx is a clinical-stage biopharmaceutical company focused on developing precision therapies for oncology, specifically targeting gastrointestinal stromal tumors. The company specializes in designing combination therapies that utilize engineered drug combinations to address key tumor escape mechanisms, aiming to enhance treatment efficacy and prolong patient responses. By creating these targeted therapies, IDRx seeks to revolutionize cancer treatment and support healthcare professionals in delivering more effective medicines to patients.
TMRW Life Sciences is a technology company focused on improving standards of safety, transparency, and accountability in the management of frozen eggs and embryos within the IVF sector. The company has developed the first automated cryo-management platform specifically designed for this purpose, which integrates a digital chain of custody with robotic storage and monitoring solutions. This innovative approach aims to replace traditional manual methods that have remained largely unchanged over the years, thereby significantly reducing the risk of errors that could have serious consequences. Founded in 2018 by Joshua Abram, Alan Murray, and Dr. Jeffrey Port, TMRW combines expertise in fertility, embryology, cryo-management, automation, software development, and robotics to enhance the specimen management process for clinics, facilitating advancements in IVF technology. The company is headquartered in New York, New York.
BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.
Century Therapeutics is a biotechnology company focused on developing advanced cell therapies using induced pluripotent stem cells (iPSCs) to treat various cancers, including hematologic and solid tumors. Founded in 2018 and based in Philadelphia, Pennsylvania, the company utilizes a unique allogeneic iPSC-derived cell therapy platform that integrates gene editing, protein engineering, and robust manufacturing capabilities. This innovative approach allows for the generation of modified immune effector cells, such as natural killer (NK) and T cells, designed to meet significant unmet medical needs. By employing techniques like CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to enhance cell product performance and minimize rejection by the host immune system, thereby improving the efficacy of cancer treatments.
Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.
Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.
Thyme Care is a healthcare company focused on providing comprehensive oncology care management services. It partners with health plans to deliver an integrated oncology solution that emphasizes whole-person care for cancer patients. By employing a tech-enabled platform, Thyme Care offers personalized support through physician-guided oncology nurses and resource specialists who educate and guide patients throughout their cancer journey. This model generates actionable insights that help healthcare providers identify at-risk patients earlier, facilitating timely access to quality resources and care. Thyme Care aims to enhance the cancer experience through early and ongoing intervention, ensuring that every cancer patient receives the individualized care they need.
Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. To produce an extended portfolio of medications, the company is developing an innovative platform at the confluence of RNA technology, delivery techniques, data analytics, and automation.
Function Oncology is a precision medicine company focused on developing advanced cancer therapies through a personalized functional genomics platform powered by CRISPR technology. This innovative platform allows for the identification of therapeutic opportunities tailored to individual patients, enhancing the understanding of cancer at a patient-specific level. By leveraging cutting-edge genomic tools, Function Oncology aims to transform targeted cancer treatment and create the next generation of therapies designed to meet the unique needs of each patient.
iVexSol Inc. specializes in developing lentiviral vector manufacturing technology aimed at addressing the shortage of lentiviral vectors (LVVs), which are essential for gene therapy programs. Established in 2018 and based in Worcester, Massachusetts, the company offers a platform that produces a consistent supply of LVVs, critical for the manufacture of cell and gene therapies (CGTs). By utilizing banks of vector-producing cells, iVexSol's technology significantly increases production capacity while minimizing complexity and development time. This innovative approach not only reduces costs but also accelerates the clinical development timelines, ultimately enhancing patient access to life-saving treatments. The company’s solutions are designed to support researchers and manufacturers in the CGT field, facilitating the treatment of serious conditions such as late-stage cancers and genetic disorders.
Nest Genomics is a lab-agnostic, comprehensive software solution for implementing genomic programs at scale.
Asimov, Inc. is a biotechnology company that specializes in the design and development of genetically engineered therapeutics. Established in 2017 and based in Cambridge, Massachusetts, Asimov focuses on creating tools for programming living cells to enhance the design and manufacturing processes of biologics and gene therapies. The company's platform integrates synthetic biology, computer-aided design, and machine learning, allowing for the engineering of genetic circuits. Asimov's multidisciplinary team employs machine-learning algorithms that connect large-scale datasets with biological models, facilitating advancements in molecular manufacturing and therapeutic applications. The company is dedicated to optimizing the production of protein biologics, viral vectors, and cell and gene therapies.
Vector Biomed is a state-of-the-art custom vector design and GMP manufacturing company. It is a source for safe, high-quality, reliably-manufactured Lentiviral vectors that are critical for producing gene medicines like CAR-T cell therapies and Stem Cell gene therapies.
LetsGetChecked is an at-home health testing platform that connects customers with regulated laboratory testing, enabling individuals to manage their health effectively. Based in New York, the company offers a wide range of testing kits for general wellness, sexual health, women's health, men's health, and specific illnesses, including cancer and fertility issues. Users can order testing kits online, collect samples such as blood or urine, and return them using prepaid envelopes. The analyzed results are then uploaded online, providing customers with convenient access to their health information. LetsGetChecked operates nationwide in the United States and extends its services to Canada and Europe, promoting a patient-led approach to healthcare through technology.
IDRx is a clinical-stage biopharmaceutical company focused on developing precision therapies for oncology, specifically targeting gastrointestinal stromal tumors. The company specializes in designing combination therapies that utilize engineered drug combinations to address key tumor escape mechanisms, aiming to enhance treatment efficacy and prolong patient responses. By creating these targeted therapies, IDRx seeks to revolutionize cancer treatment and support healthcare professionals in delivering more effective medicines to patients.
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.
Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.
Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.
Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.
Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that specializes in the development and manufacture of proteins and enzymes for various applications, including pharmaceuticals, polymers, and industrial chemicals. Founded in 2008, Arzeda utilizes advanced technology that combines physics-based protein design with artificial intelligence algorithms to create and validate new designer proteins and enzymes. The company aims to provide innovative solutions that offer competitive performance, cost efficiency, and sustainability, addressing the needs of clients in diverse industries.
Celsius Therapeutics is a biotechnology company focused on developing precision medicines for patients with cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a team of scientists, technologists, computational biologists, clinicians, and drug hunters. Utilizing single-cell genomic analysis and machine learning techniques, Celsius Therapeutics aims to discover and create innovative therapies that can lead to significant improvements in patient outcomes. The company's research efforts are centered on identifying new drug candidates that address unmet medical needs in the therapeutic landscape.
InnoSIGN specializes in mRNA-based pathway activity profiling technology, aimed at advancing precision medicine by offering deeper insights into disease mechanisms. The company leverages a comprehensive library of pathway activity profiles to enhance diagnostics and facilitate drug discovery. It provides researchers with quantitative PCR (qPCR) tests designed for decentralized use, which are available through a service testing facility located in the Netherlands. Through its innovative approach, InnoSIGN seeks to transform the understanding and treatment of various diseases.
Deepcell, Inc. is a biotechnology company based in Mountain View, California, that specializes in providing advanced diagnostic solutions through its innovative microfluidic imaging platform. Founded in 2015, the company focuses on delivering non-invasive tests with diagnostic-level accuracy, enabling researchers and clinicians to gain insights at the single-cell level. Deepcell's technology employs artificial intelligence to analyze and classify cells based on their morphological features, isolating viable cells for various applications in translational research, diagnostic testing, and therapeutics. By utilizing ordinary blood samples, Deepcell enhances the understanding of genetic health without the need for invasive procedures, thereby improving the diagnosis and treatment of diseases.
22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021.
Molecular Assemblies, Inc. is a San Diego-based company specializing in enzymatic DNA synthesis technology, which facilitates the development of DNA-based products across various industries. Founded in 2013, the company focuses on creating long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner, inspired by natural processes. Its technology has applications in industrial synthetic biology, personalized therapeutics, precision diagnostics, information storage, nanotechnology, and DNA electronics. The firm boasts a skilled executive and scientific team, supported by a robust intellectual property portfolio. Molecular Assemblies has garnered investments from a range of venture capital sources, indicating strong interest in its innovative approach to DNA synthesis.
Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in developing tools for biological automation, focusing on scalable automation solutions for genetic engineering. Volta Labs operates a platform designed for affordable genomic sample preparation, aimed at revolutionizing genomics research. This platform leverages automation and miniaturization technologies to streamline the creation of biological samples. By integrating expertise from engineering, surface chemistry, and molecular biology, Volta Labs enables biotech organizations to automate complex biological workflows, facilitating advancements in genomics and genetic engineering.
Creyon Bio is a pre-clinical stage company reimagining drug development as it should be, using a data-first approach for generating uniquely powerful datasets and developing machine learning models to uncover the engineering principles that make precision oligonucleotide-based medicines possible for patient populations of all sizes.
Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule medicines aimed at treating autoimmune diseases, inflammatory diseases, and cancer by targeting the innate immune system. The company employs a structural immunology platform that provides deep insights into the mechanisms and molecular structures involved in immune responses. This platform integrates proprietary protein engineering capabilities with advanced rational and structure-based drug design tools, allowing for precise targeting of the innate immune system. Ventus is actively building a pipeline of drug programs that address critical targets within this system, particularly proteins involved in inflammasome and nucleic acid-sensing signaling pathways, thereby enabling the treatment of both acute and chronic inflammatory and immune-related conditions.
Septerna is a biotechnology company focused on discovering and advancing novel small-molecule medicines that target G protein-coupled receptors (GPCRs). The company aims to improve patient outcomes by integrating innovative drug discovery technologies with GPCR drug targets. Utilizing its Native Complex platform, Septerna facilitates industrial-scale drug discovery through advanced screening technologies and structure-based drug design. This approach enables medical researchers to efficiently identify treatments for a variety of diseases.
Leyden Labs is focused on developing intranasal products that aim to protect individuals from respiratory viruses, including those in the influenza and coronavirus families. The company's innovative approach targets common characteristics across various viral families, allowing for simultaneous protection against multiple viruses rather than just specific variants, as is the case with traditional vaccines. This strategy seeks to empower individuals to safeguard themselves from infections and reduce the transmission of these diseases. Leyden Labs is driven by a team of experienced biotechnology professionals who are committed to advancing solutions that alleviate the impact of respiratory viruses on public health.
Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.
Maze Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative medicines that leverage the effects of rare genetic variants to address unmet medical needs. Founded in 2017 and originally known as Modulus Therapeutics, the company utilizes its proprietary Compass platform to identify genetic variants linked to diseases and map them to the biological pathways that drive these conditions in specific patient populations. By integrating large-scale human genetics data and functional genomics with various drug discovery methods, Maze Therapeutics aims to reveal modifier genes that offer protective benefits. This approach enhances the understanding of target biology and informs the development of novel therapies, ultimately enabling pharmaceutical companies to create effective treatments.
DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.
ONI is a leader in super-resolution microscopy, offering innovative tools that enhance biological research. The company has developed the Nanoimager, the first benchtop super-resolution microscope, which provides unprecedented usability and precision for researchers. This device enables access to various super-resolution techniques, including dSTORM, PALM, smFRET, and single-particle tracking, facilitating a deeper understanding of cellular structures and functions. ONI's products are increasingly adopted by academic researchers and pharmaceutical companies, with installations in prominent laboratories such as those at the Universities of Oxford, Cambridge, and Harvard. The company's mission is to democratize scientific discovery by making advanced imaging technology more accessible and affordable, thereby empowering researchers to visualize and share the intricate details of life. Recognized for its innovative contributions, ONI has received accolades such as being named a Disruptor to Watch and winning Best Business Start-up at the IOP Awards. Through its commitment to advancing scientific research, ONI aims to accelerate discoveries that can lead to improved health outcomes.
Apella is an artificial intelligence startup focused on enhancing surgical procedures through advanced healthcare technology. Founded in 2019 and headquartered in San Francisco, California, the company develops systems that utilize AI, computer vision, and modern communication to digitize operating rooms. By collecting data from these environments via sensors, Apella analyzes the information to provide insights that can improve surgical quality, streamline operations, and aid in training and real-time decision-making for medical staff. Its innovative approach aims to elevate surgery outcomes and optimize the overall efficiency of healthcare delivery.
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.
Depixus is a biotechnology company that has developed a novel technology designed for real-time analysis of individual biomolecular interactions at a large scale. Its platform enables comprehensive genome analysis, allowing researchers to examine entire genomic regions quickly and efficiently. This integrated system provides the flexibility to specify the desired level of sequence and epigenetic detail, facilitating the discovery of new biological pathways and the decoding of disease mechanisms. By enhancing the understanding of these processes, Depixus aims to contribute to the development of new precision medicines. The company's focus on advanced DNA and RNA sequencing technologies addresses the limitations of current methods, particularly in achieving single-molecule precision.
Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.
Exai Bio is a next-generation liquid biopsy company. Exai bio proprietary RNA and artificial intelligence-based liquid biopsy platform deliver clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.
Nomic is a bioengineering company focused on making the human proteome as accessible as the human genome. The company is developing the nELISA, a next-generation platform for measuring proteins at high throughput and scale. Nomic provides scientists with protein profiling solutions, allowing them to determine the scope and scale of their experiments. Their platform features cost-effective measurement of protein data and integrates smoothly with industry-standard cytometers for high-throughput analysis. Additionally, Nomic's technology enables the development of custom protein panels, leveraging nanotechnology to use DNA as a versatile linker to address issues of cross-reactivity in protein measurement.
Lunit Inc. is a medical AI software company based in Seoul, South Korea, specializing in advanced algorithms for medical image analysis and general object detection. The company develops solutions for various medical imaging modalities, including digital chest X-ray, digital mammography, digital pathology, and fundus photography. Lunit aims to enhance clinical decision-making for physicians by leveraging machine learning technology to provide accurate and consistent diagnoses. Its product offerings include Lunit INSIGHT CXR for chest X-rays, Lunit INSIGHT MMG for mammography, and Lunit SCOPE, which includes AI-powered biomarkers for immuno-oncology. Lunit's deep learning technology has been recognized for its capabilities, ranking among the top in prestigious image recognition competitions, highlighting its innovative approach to processing medical imaging data and utilizing weakly labeled data for improved pattern recognition.
Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.
Chroma Medicine is a genomic medicine company based in Cambridge, Massachusetts, founded in 2021. The company focuses on epigenetic editing, aiming to revolutionize the treatment of genetically driven diseases. By utilizing epigenetics, which is nature's inherent mechanism for regulating genes, Chroma Medicine develops programmable epigenetic editors that target specific genes and control chromatin conformation. This innovative approach combines a DNA binding domain with epigenetic effector domains, providing medical practitioners with a new class of therapeutics that offers enhanced control over gene expression.
Beacon Biosignals is focused on enhancing human health through artificial intelligence applied to brain activity analysis. The company has developed an EEG analysis and diagnosis platform that delivers reports with remarkable speed and accuracy, significantly reducing the need for adjudication by utilizing improved inclusion and exclusion criteria. This platform captures real-time brain activity and aids healthcare professionals in studying neurological and psychiatric conditions. By providing advanced brain analytics, Beacon Biosignals enables clinicians to quantify treatment plans and identify the most suitable patient populations for targeted interventions.
Qloudlab is a pioneering company known for inventing the world's first touchscreen-based biosensor. The company has developed Sceptre, a modular platform that enables multiple diagnostics at the Point-of-Care through a single, mobile device capable of conducting various tests, including blood, urine, saliva, and skin analyses. This innovative technology bridges the gap between smartphones, healthcare, and cloud solutions, offering a cost-effective approach to diagnostics. Complementing this, Loop Medical focuses on revolutionizing blood collection by providing a needleless, pain-free technology. This device collects blood samples using a proprietary cartridge that integrates seamlessly with standard laboratory processes, enhancing the convenience for both patients and healthcare professionals. Together, these innovations represent a significant advancement in accessible and efficient medical diagnostics.
Basilard BioTech operates a technology platform focused on advancing cell-based therapies, particularly in the field of Cell and Gene Therapies (CGT). This platform utilizes a nanomechanical gene delivery method, distinguishing itself by providing a mechanical approach to gene delivery rather than relying on biological processes. This innovative technique consistently achieves higher transfection rates, enhanced cell viability, and improved yields, thereby allowing clients to optimize their therapeutic outcomes. By harnessing the potential of cell functions, Basilard BioTech aims to address critical unmet clinical needs and contribute to solutions for diseases that impact millions of lives.
Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing intractable pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to develop a pipeline of drug candidates. These candidates are designed to bind to exosites and unique binding pockets, allowing for the reprogramming of enzyme activity to achieve targeted therapeutic effects. This innovative approach aims to provide robust treatments in areas such as oncology and inflammation, while also minimizing potential side effects for patients. By employing a precise and selective methodology, Exo Therapeutics is positioned to unlock new therapeutic possibilities for a variety of diseases.
Thyme Care is a healthcare company focused on providing comprehensive oncology care management services. It partners with health plans to deliver an integrated oncology solution that emphasizes whole-person care for cancer patients. By employing a tech-enabled platform, Thyme Care offers personalized support through physician-guided oncology nurses and resource specialists who educate and guide patients throughout their cancer journey. This model generates actionable insights that help healthcare providers identify at-risk patients earlier, facilitating timely access to quality resources and care. Thyme Care aims to enhance the cancer experience through early and ongoing intervention, ensuring that every cancer patient receives the individualized care they need.
Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.
Ginkgo Bioworks is a biotechnology company based in Boston, Massachusetts, founded in 2008. It specializes in biological engineering, designing and developing custom microbes and organisms for various applications. The company discovers and licenses molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, it offers probiotic bacteria aimed at protecting against infections and creates libraries of molecules for natural product discovery. Ginkgo Bioworks operates primarily in the markets of cultured ingredients, carbon mitigation, probiotics, and biosecurity. The biosecurity segment, which generates the majority of the company's revenue, provides data analytics and related services to organizations across diverse sectors, including food, agriculture, pharmaceuticals, and specialty chemicals.
Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients suffering from neurodegenerative diseases. The company leverages a technology platform that incorporates human genetics and patient-derived neuronal cells to identify and validate new disease pathways linked to lysosomal dysfunction and the inappropriate activation of the innate immune system. Vanqua Bio focuses on creating small-molecule activators of glucocerebrosidase and advancing programs that target the innate immune system, with the aim of addressing the progression of various neurological disorders. Through its efforts, the company seeks to provide healthcare professionals with transformative treatment options for patients facing these challenging conditions.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.
Xcell Biosciences, Inc. is a San Francisco-based life science start-up founded in 2012, focused on developing innovative technologies for cancer cell analysis and immunotherapy. The company specializes in a bench-top primary cell control system that captures, grows, and analyzes cancer cells directly from patient blood samples. Their proprietary technology allows for precise control of primary cell phenotype and function, enhancing the efficacy and persistence of immune cell therapies. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences provides researchers with advanced tools for cell maintenance and expansion, ultimately aiming to improve therapy development and clinical outcomes.
SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. The company utilizes its proprietary technology platform, SomaScan, which allows for the measurement of proteins with a precision comparable to DNA measurement. This technology enhances the understanding of the molecular bases of health and disease, surpassing traditional genomic methods. SomaLogic develops and offers SOMAmers, modified nucleic acid-based protein-binding reagents, and provides diagnostic tests and protein measurement solutions for various diseases, including those in oncology, neurology, and cardiovascular health. Their products serve multiple applications, including life sciences research, therapeutic drug development, and clinical diagnostics, making significant contributions to the fields of biological and medical sciences. Founded in 1999, SomaLogic continues to advance the capabilities of proteomics in both research and clinical settings.
NanoCellect Biomedical, Inc. is a company based in San Diego, California, specializing in the development of innovative flow cytometry and cell sorting technologies for life science researchers. Founded in 2009, it offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to enable efficient cell sorting while minimizing biohazard risks and shear stress associated with traditional methods. The company’s portfolio includes affordable and compact microfluidic-based instruments and consumables that facilitate cellular analysis essential for drug discovery, single cell-omics, cloning, antibody discovery, and basic research. By simplifying the process of analyzing and sorting distinct cell populations, NanoCellect Biomedical supports biomedical scientists in advancing their research and improving personalized medicine.
Zentera Therapeutics is a biopharmaceutical company.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
Genomatica, Inc. is a biotechnology company based in San Diego, California, that specializes in developing manufacturing processes to produce intermediate and basic chemicals from renewable feedstocks. Utilizing a proprietary platform, the company creates fermentation-based processes and engineers microorganisms that facilitate the conversion of these feedstocks into valuable chemicals. Genomatica has commercialized processes for butanediol, used in biodegradable plastics and apparel, and butylene glycol, which is utilized in cosmetics and personal care products. The company is also advancing the development of bio-nylon and has a pipeline targeting the production of 20 different chemicals, including butadiene. Recognized for its innovative technology, Genomatica has received several awards, including the Kirkpatrick Award for notable chemical engineering advancements and the ICIS Innovation Award for its Brontide butylene glycol.
GeneDx is dedicated to providing personalized health insights that enhance diagnosis, treatment, and drug discovery. By integrating extensive genomic expertise with advanced data interpretation capabilities, the company aims to establish precision medicine as a standard in healthcare. GeneDx specializes in exome and genome testing and interpretation, leveraging one of the largest rare disease data sets available. Its operations are divided into two segments: GeneDx, which generates the majority of revenue, and Legacy Sema4 diagnostics. Through these efforts, GeneDx is positioned to significantly impact health outcomes by using genomic and large-scale clinical information.
TMRW Life Sciences is a technology company focused on improving standards of safety, transparency, and accountability in the management of frozen eggs and embryos within the IVF sector. The company has developed the first automated cryo-management platform specifically designed for this purpose, which integrates a digital chain of custody with robotic storage and monitoring solutions. This innovative approach aims to replace traditional manual methods that have remained largely unchanged over the years, thereby significantly reducing the risk of errors that could have serious consequences. Founded in 2018 by Joshua Abram, Alan Murray, and Dr. Jeffrey Port, TMRW combines expertise in fertility, embryology, cryo-management, automation, software development, and robotics to enhance the specimen management process for clinics, facilitating advancements in IVF technology. The company is headquartered in New York, New York.
Hexagon Bio, Inc. is a biotechnology company based in Menlo Park, California, focused on discovering novel drugs for diseases that lack effective treatments. Established in 2016, the company utilizes a data-driven approach that combines genomics, synthetic biology, and computational techniques. By mining genomic data from fungal genomes, Hexagon Bio aims to identify targeted small molecule therapeutics. Its proprietary platform leverages data science to engineer drugs from DNA sequences, enabling the identification of small molecule inhibitors that interact with specific target proteins. This innovative method allows researchers to tap into the global metagenome, facilitating the development of new medicines aimed at improving patient outcomes.
Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.
23andMe, Inc. is a consumer genetics company based in Sunnyvale, California, founded in 2006. It offers DNA analysis services through home-based saliva collection kits, enabling consumers to explore their genetic ancestry, traits, and health predispositions. The company provides various services, including Health + Ancestry, which delivers insights into ancestry and genetic health risks, and Ancestry + Traits, which offers an ancestry breakdown along with reports on over 30 traits. Additionally, 23andMe markets its data to researchers and scientists, providing them with categorized and searchable genetic information. The firm aims to enhance understanding of the human genome and its implications for health and ancestry. Through its consumer and research services, 23andMe seeks to make genetic information accessible and meaningful to individuals and professionals alike.
Mnemo Therapeutics is a biotechnology firm focused on developing immune-based therapies, particularly cell therapies, aimed at treating solid tumors and blood cancers. The company utilizes its EnfiniT platform, a drug discovery engine that harnesses a unique class of antigens and various technologies to target tumorous epitopes prevalent in multiple cancer types. By leveraging epigenetic variation and CAR-T precision genetic engineering, Mnemo Therapeutics strives to create accessible allogeneic treatments that offer effective solutions for patients facing these challenging diseases.
Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.
LetsGetChecked is an at-home health testing platform that connects customers with regulated laboratory testing, enabling individuals to manage their health effectively. Based in New York, the company offers a wide range of testing kits for general wellness, sexual health, women's health, men's health, and specific illnesses, including cancer and fertility issues. Users can order testing kits online, collect samples such as blood or urine, and return them using prepaid envelopes. The analyzed results are then uploaded online, providing customers with convenient access to their health information. LetsGetChecked operates nationwide in the United States and extends its services to Canada and Europe, promoting a patient-led approach to healthcare through technology.
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.
Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company aims to identify 'switch sites,' which are druggable regions crucial for regulating transcription factors, to target mutations associated with various diseases. Flare's innovative approach has advanced its drug discovery efforts, resulting in a promising pipeline of programs that primarily address well-established transcription factors. Initially concentrating on precision oncology, the company's research also holds potential applications in neurology, rare genetic disorders, immunology, and inflammation. By leveraging insights from its scientific founders, Flare Therapeutics seeks to transform the treatment landscape for cancer patients and other disease areas.
Scribe Biosciences specializes in single-cell analysis tools that enhance clinical and research applications. The company employs its proprietary technology, Printed Droplet Microfluidics (PDM), which allows for flexible and reconfigurable fluid handling at the picoliter scale. By utilizing fluorescence-activated microfluidic droplet sorting along with a specialized substrate, Scribe Biosciences can manipulate single cells and fluid aliquots with high throughput. This innovative approach aids researchers and healthcare professionals in gaining insights into various processes, particularly those related to infectious diseases and cancer.
Dyno Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative adeno-associated virus (AAV) vectors for gene therapy applications. Founded in 2018, the company employs an artificial intelligence-powered platform that integrates next-generation DNA synthesis, high-throughput sequencing, and machine learning. This advanced approach allows Dyno Therapeutics to design and optimize cell-targeting capsids, which are crucial for the effective and safe delivery of gene therapies. By leveraging its technology, the company aims to provide medical researchers with novel AAV vectors that enhance the efficacy of in vivo therapeutic solutions.
Apton Biosystems, Inc., founded in 2012 and located in Pleasanton, California, operates within the biotechnology industry, focusing on advanced medical technology. The company has developed an innovative optical system for sequencing and protein detection that utilizes super-resolution techniques. This technology allows for the assessment of molecules situated closer than the wavelength of light, facilitating multi-omic sequencing and single-molecule protein detection. Apton's solutions aim to enhance biomarker discovery, enable early disease detection, and support therapeutic monitoring, thereby contributing to advances in preventive health and precision medicine.
Treeline Biosciences is a biotechnology company established in 2021 and based in Stamford, Connecticut. The company focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. Utilizing a comprehensive drug discovery platform, Treeline combines mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science to create innovative therapeutic solutions. Through its research and development efforts, Treeline aims to provide effective treatments to improve patient outcomes in oncology and beyond.
Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.
C2i Genomics, Inc. specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-surgery cancer patients. The company offers liquid biopsy services that analyze subtle changes in tumor DNA to provide insights into cancer progression and recurrence. This technology enables the development of a bio-platform approach applicable across various cancer types, facilitating the guidance of diverse treatment modalities, including surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enhancing the ability of healthcare providers to monitor treatment responses and detect recurrences or failures earlier than traditional methods allow. Founded in 2019 and headquartered in New York, with a research and development center in Haifa, Israel, C2i Genomics aims to improve the lives and outcomes of cancer patients through innovative diagnostic solutions.
Multiply Labs specializes in the production of personalized pharmaceutical capsules that cater to the unique needs of individual patients. The company leverages a combination of pharmaceutical science and advanced robotics technology to create these tailor-made capsules. Its innovative approach includes operating a state-of-the-art robotic manufacturing facility, which allows for the efficient production of individualized drugs at a reduced cost. Multiply Labs stands out as a pioneer in the industry, being the first to introduce 3D printed capsules, thereby transforming how medications are customized to meet the specific metabolic requirements of patients.
Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule medicines aimed at treating autoimmune diseases, inflammatory diseases, and cancer by targeting the innate immune system. The company employs a structural immunology platform that provides deep insights into the mechanisms and molecular structures involved in immune responses. This platform integrates proprietary protein engineering capabilities with advanced rational and structure-based drug design tools, allowing for precise targeting of the innate immune system. Ventus is actively building a pipeline of drug programs that address critical targets within this system, particularly proteins involved in inflammasome and nucleic acid-sensing signaling pathways, thereby enabling the treatment of both acute and chronic inflammatory and immune-related conditions.
SeQure Dx specializes in providing safety data related to CRISPR gene editing therapies, focusing on both on-target and off-target effects. The company develops genomics diagnostic technologies that facilitate target profiling for gene editing, supporting the discovery, clinical development, and diagnostic processes. Its core technologies are designed to identify potential off-target sites prior to the initiation of therapy, ensuring comprehensive confirmation of actual genetic edits. This capability empowers gene editing therapeutics developers, physicians, and patients by enhancing the safety and efficacy of gene editing treatments.
Leyden Labs is focused on developing intranasal products that aim to protect individuals from respiratory viruses, including those in the influenza and coronavirus families. The company's innovative approach targets common characteristics across various viral families, allowing for simultaneous protection against multiple viruses rather than just specific variants, as is the case with traditional vaccines. This strategy seeks to empower individuals to safeguard themselves from infections and reduce the transmission of these diseases. Leyden Labs is driven by a team of experienced biotechnology professionals who are committed to advancing solutions that alleviate the impact of respiratory viruses on public health.
Absci is a drug and target discovery company that utilizes deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. By employing its Integrated Drug Creation Platform, Absci identifies novel drug targets and discovers optimal biotherapeutic candidates while simultaneously generating the necessary cell lines for manufacturing. This innovative approach allows biotech and pharmaceutical partners to develop next-generation protein-based drugs, including Bionic Proteins that incorporate nonstandard amino acids and other unique drug designs that may be unattainable through traditional methods. Absci's mission focuses on advancing the development of improved medicines by effectively translating innovative ideas into viable drugs.
Komodo Health Inc. is a healthcare technology company that specializes in providing real-time healthcare intelligence and transparency through its innovative platform. Founded in 2014 and based in New York, with an additional office in San Francisco, the company offers a suite of software solutions, including its Healthcare Map, which tracks patient outcomes across the healthcare system. The platform utilizes advanced data science techniques and artificial intelligence to deliver insights that empower various stakeholders in the healthcare sector, including life science companies, payers, and providers. Key products such as Aperture, Pulse, and Serenity facilitate the analysis of complex healthcare connections, alert users to influence disease burden positively, and explore patient cohorts for deeper insights. By enabling a more cost-effective and value-driven healthcare system, Komodo Health aims to set a new standard for real-world data and analytics in the industry.
Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.
Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.
Palamedrix is a biotechnology company based in San Diego, California, founded in 2017 by Shane Bowen. The company focuses on developing a multi-omic platform that utilizes DNA nanotechnology to enhance advancements in life science and medicine. By providing comprehensive data, Palamedrix aims to deliver innovative solutions for biomedical applications, enabling healthcare professionals and patients to obtain an accurate and complete view of an individual's biochemistry through a single test.
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to the nervous system.
Notch Therapeutics Inc. is an immune cell therapy company focused on developing gene-edited allogenic T cell therapies for cancer treatment. Based in Toronto, Canada, the company utilizes a proprietary platform for induced pluripotent stem cell (iPSC) technology that allows for precision control of Notch signaling, which is essential for T cell development. This innovative approach addresses critical limitations in cell therapy development, enabling the design and manufacture of a consistent and limitless supply of therapeutic T cells. Notch Therapeutics aims to provide targeted treatments for conditions such as non-Hodgkin lymphoma, leukemia, and multiple myeloma, facilitating advancements in the treatment of complex disease systems. Established in 2018, the company is positioned at the forefront of next-generation cancer therapies.
Imagen enables Primary Care providers to become technology-enabled multispecialty practices, powering a successful transition from fee-for-service to value-based care. Its comprehensive platform includes in-office diagnostic testing, diagnostic interpretations powered by proprietary FDA-cleared machine learning software, and virtual specialist consults. Its platform empowers Primary Care providers to achieve healthcare’s quadruple aim of increasing quality, lowering costs, and improving the patient and provider experience.
Orchard Therapeutics is a biopharmaceutical company based in the United Kingdom that specializes in developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which modifies a patient's own hematopoietic stem cells to create a targeted treatment administered in a single dose. Orchard's portfolio includes Strimvelis, the first autologous gene therapy approved by the European Medicines Agency for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Additionally, it is advancing clinical programs for various conditions, including metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has an extensive preclinical pipeline targeting mucopolysaccharidosis types I, IIIA, and IIIB. Orchard Therapeutics collaborates with leading institutions in gene therapy research, enhancing its efforts to transform the lives of patients with rare diseases in the UK, European Union, and the United States. Founded in 2015 and headquartered in London, it aims to provide sustainable clinical benefits through its innovative therapies.
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients with serious diseases. Its therapeutic portfolio includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, and glycogen storage disorder 1A, as well as therapies for ocular and central nervous system disorders. Beam's base editing technology allows for targeted modifications at a single base in the genome without creating double-stranded breaks in DNA, positioning it as a pioneer in the field of genetic medicine. The company's pipeline includes several programs, such as BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201, reflecting its commitment to advancing genetic therapies.
Paige, founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializes in computational pathology products that enhance cancer diagnostics. The company has developed a platform utilizing advanced deep learning algorithms to improve diagnostic stratification and cancer detection, particularly for breast and prostate cancers. This innovative technology aims to empower patients and their care teams to make informed treatment decisions by providing pathologists with critical insights for more accurate diagnoses. Paige's user-friendly platform minimizes the burden on IT resources while ensuring patient safety and data privacy. As a pioneer in the field, Paige has achieved FDA breakthrough designation for its computational pathology products, positioning itself at the forefront of transforming pathology workflows and increasing diagnostic confidence.
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.
FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.
Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company's platform generates, analyzes, and integrates data to provide a comprehensive approach aimed at reducing the overall cost of care. By optimizing healthcare medications and utilization, Octave enables pharmaceutical companies to enhance the entire lifecycle of drug discovery, clinical trials, and post-marketing processes through the use of real-world evidence. This innovative approach seeks to improve patient outcomes while streamlining healthcare practices.
Neurogene is a developer of generic medicines intended to improve patient outcomes for neurological disorders.The company's offerings include advancing genetic medicines for many neurological disorders where no effective treatment options exist, providing patients and families affected by rare neurological disorders with gene therapy that improves quality of life.